Corstasis Therapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Corstasis Therapeutics is an early-stage biotech company targeting the significant unmet need for home-based fluid removal in patients with congestive heart failure and related organ diseases. The company is building a leadership team and advisory board with deep expertise in cardiovascular pharmaceuticals, medical devices, and clinical cardiology. While specific pipeline details are not publicly disclosed, its mission centers on shifting fluid overload management from inpatient to outpatient settings, potentially improving patient quality of life and reducing healthcare system burdens.

CardiovascularNephrologyHepatology

Technology Platform

Novel drug delivery platform for outpatient management of fluid overload.

Opportunities

The massive and growing patient population with CHF and related organ diseases creates a multi-billion dollar addressable market for a therapy that can reduce costly hospital readmissions.

The shift towards value-based care and remote patient monitoring creates a favorable environment for home-based therapeutic solutions.

Success could lead to a lucrative partnership or acquisition by a larger pharmaceutical or medtech company with a footprint in cardiorenal diseases.

Risk Factors

The core scientific and clinical risk is high, as developing a safe and effective home-administered therapy for acute fluid overload is a significant challenge.

The company is at an early, pre-revenue stage and is dependent on raising external capital to fund development through expensive clinical trials.

It faces competition from both optimized pharmaceutical diuretics and mechanical fluid removal devices.

Competitive Landscape

Corstasis competes in the broad heart failure and fluid management market, which includes large pharma companies with diuretic portfolios (e.g., AstraZeneca, Novartis), companies developing novel diuretics (e.g., Bayer, Cardurion), and medical device firms with ultrafiltration systems (e.g., Sequana Medical, CHF Solutions). Its key differentiation is the focus on an intuitive, home-based drug delivery platform, a niche with fewer direct competitors but significant technical hurdles.

More companies in Drug Delivery & Formulation →More companies in United States →